error fb Gplus IN twitter down-arrow Email Phone Check-Mark padlock circle_arrow minus plus play_btn close Clipboard_Icon Shopping-Cart_Icon Speech_Bubble_Icon Stethoscope_Icon pharmacists menu left-arrow right-arrow facebook search cart

DIaMonD Study Shows Dexcom Continuous Glucose Monitoring (CGM) Benefits > 


Medicare Coverage Announced >


Now Approved for Diabetes Treatment Decisions* >



*Fingersticks required for calibration, or if symptoms or expectations do not match readings, or when taking medications containing acetaminophen.

Who Can Benefit from CGM?

Many of your patients struggle to maintain good glycemic control, despite their best intentions. Whether your patient has type 1 or type 2 diabetes, or they are being treated with an insulin injection regimen or pump therapy – they may benefit from CGM.

Who Can Benefit from CGM?

  • Uncontrolled type 1 and type 2 diabetes
  • On insulin injections or insulin pump therapy
  • Hypoglycemia unawareness
  • At or above A1C goal

We offer two CGM options for your patients

Personal CGM

The Dexcom G5® Mobile CGM System, our most current CGM patient platform, is approved for patients 2 years and older. This fully mobile System gives patients the ability to view their glucose data directly on a compatible mobile device.1

Professional CGM

The Dexcom G4® PLATINUM Professional CGM System is practice-owned and gives you real-time feedback and insights about your patient’s glycemic control, which can inform therapeutic treatment recommendations. The System can be blinded when clinically necessary.

CGM Drives A1C Reduction

The COMISAIR Study2 shows similar A1C reductions in patients whether they are on multiple daily injections (MDI) insulin regimen (1.3%) or insulin pump therapy (1.1%)



2Šoupal J, Petruželková L, Flekač M et al. Comparison of Different Treatment Modalities for Type 1 Diabetes, Including Sensor-Augmented Insulin Regimens, in 52 Weeks of Follow-Up: A COMISAIR Study. Diabetes Technology & Therapeutics. 2016;18(9):532-538.

Approved for use in treatment decisions

The Dexcom G5 Mobile Continuous Glucose Monitoring (CGM) System is the first CGM system approved as a replacement of fingersticks for treatment decisions (“non-adjunctive use”). Now your patients can rely on the accuracy of the Dexcom G5 Mobile to dose for a high and eat for a low—without the pain and hassle of a fingerstick.  


*Fingersticks required for calibration, or if symptoms or expectations do not match readings, or when taking medications containing acetaminophen.

Support and Education

Dexcom will be your trusted partner in bringing CGM to your practice and patients. We assist with patient onboarding, including verification of insurance coverage, as well as provide clinician and patient training and education about CGM and the Dexcom products.

More information

For more information, or to get started with adding CGM to your practice, click one of the links below to be contacted by a Dexcom representative.

1 To view a list of compatible devices, visit


BRIEF SAFETY STATEMENT The Dexcom G5 Mobile Continuous Glucose Monitoring (CGM) System ("G5") is a glucose monitoring system indicated for detecting trends and tracking patterns in persons (age 2 years and older) with diabetes. CONTRAINDICATIONS Do not rely on the G5 CGM data if you have recently taken acetaminophen. Remove the G5 (sensor, transmitter, and receiver) before Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scan, or high-frequency electrical heat (diathermy) treatment. The G5 is MR Unsafe. Do not bring any portion of the G5 into the MRI environment. WARNING CGM-based diabetes treatment decisions are only approved with the G5, not previous generations of Dexcom CGM systems. Calibrate at least once every 12 hours using a fingerstick. If your G5 does not display a sensor glucose reading and an arrow, or if you are getting inaccurate or inconsistent readings, take a fingerstick. If your glucose readings and alerts do not match your symptoms or expectations, take a fingerstick to confirm. Failure to do so may lead to hyperglycemia or hypoglycemia. The G5 is not approved for use in pregnant women, persons on dialysis or critically ill persons. If a sensor breaks and no portion of it is visible above the skin, do not attempt to remove it. Seek professional medical help if you have infection or inflammation on or near the sensor insertion point. Report broken sensors to Dexcom Technical Support. Sensor placement is not approved for sites other than under the skin of the belly (ages 2 years and older) or upper buttocks (ages 2-17 years). To “share” data, you need an internet connection and a separate compatible smart device running the Dexcom Follow App. Contact Dexcom Toll Free at 877-339-2664 or for detailed indications for use and safety information.

LBL014047 Rev 003